Related Experiment Videos
Genetic alterations in hormone-refractory recurrent prostate carcinomas
N N Nupponen1, L Kakkola, P Koivisto
1Laboratory of Cancer Genetics, Institute of Medical Technology, University of Tampere and Tampere University Hospital, Finland.
The American Journal of Pathology
|July 17, 1998
Summary
Recurrent prostate carcinomas exhibit significant genetic instability, with frequent chromosomal aberrations like 8p loss and 8q gain. This genetic diversity may explain their resistance to hormone therapy.
Area of Science:
- Oncology
- Genetics
- Cancer Biology
Background:
- Hormone-refractory prostate cancer (HRPC) poses a significant clinical challenge due to its aggressive nature and poor treatment response.
- Understanding the genetic underpinnings of tumor progression in HRPC is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the genetic alterations associated with tumor progression in hormone-refractory prostate carcinomas.
- To identify recurrent genetic aberrations and assess their correlation with tumor behavior.
Main Methods:
- Comparative genomic hybridization (CGH) was employed to screen 37 hormone-refractory prostate carcinomas for genetic changes.
- Fluorescence in situ hybridization (FISH) was used to validate CGH findings and analyze specific gene copy numbers (c-myc, bcl-2).
- Analysis of primary-recurrent tumor pairs evaluated clonal relationships.
Main Results:
- All recurrent tumors displayed genetic aberrations, with an average of 11.4 changes per tumor.
- Frequent chromosomal losses included 8p, 13q, and 1p, while gains were common at 8q, 7q, and Xq.
- CGH and FISH showed concordance, with increased copy numbers of c-myc and bcl-2 observed in a subset of tumors. Fifty percent of primary-recurrent pairs showed clonal relationships.
Conclusions:
- Hormone-refractory prostate carcinomas are characterized by significant genetic instability.
- The observed genetic heterogeneity likely contributes to the resistance of these tumors to therapeutic interventions.
- Further research into these genetic alterations may reveal novel therapeutic targets for HRPC.